The stock of Fluidigm Corporation (NASDAQ:FLDM) is a huge mover today! The stock increased 4.99% or $0.29 on November 23, hitting $6.1. About 208,312 shares traded hands. Fluidigm Corporation (NASDAQ:FLDM) has declined 39.48% since April 22, 2016 and is downtrending. It has underperformed by 44.89% the S&P500.
The move comes after 7 months positive chart setup for the $164.59 million company. It was reported on Nov, 24 by Barchart.com. We have $6.41 PT which if reached, will make NASDAQ:FLDM worth $8.23M more.
Analysts await Fluidigm Corporation (NASDAQ:FLDM) to report earnings on February, 2. They expect $-0.45 earnings per share, down 18.42% or $0.07 from last year’s $-0.38 per share. After $-0.50 actual earnings per share reported by Fluidigm Corporation for the previous quarter, Wall Street now forecasts -10.00% EPS growth.
Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage
Out of 5 analysts covering Fluidigm (NASDAQ:FLDM), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Fluidigm has been the topic of 17 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Mizuho given on Sunday, August 9. The company was initiated on Wednesday, August 26 by Cantor Fitzgerald. The firm has “Hold” rating by Maxim Group given on Thursday, August 27. Piper Jaffray downgraded Fluidigm Corporation (NASDAQ:FLDM) rating on Friday, August 7. Piper Jaffray has “Neutral” rating and $15 price target. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Buy” rating by Deutsche Bank on Thursday, January 7. The firm has “Sell” rating by Zacks given on Friday, August 21. As per Friday, February 5, the company rating was upgraded by Mizuho. The rating was maintained by Cantor Fitzgerald on Friday, August 5 with “Buy”. The rating was maintained by Mizuho with “Neutral” on Friday, August 7. Mizuho maintained the stock with “Buy” rating in Friday, August 5 report.
According to Zacks Investment Research, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California.”
Insitutional Activity: The institutional sentiment increased to 1.35 in 2016 Q2. Its up 0.53, from 0.82 in 2016Q1. The ratio increased, as 14 funds sold all Fluidigm Corporation shares owned while 31 reduced positions. 8 funds bought stakes while 29 increased positions. They now own 25.56 million shares or 9.86% less from 28.35 million shares in 2016Q1.
Metropolitan Life Insurance last reported 0% of its portfolio in the stock. Thompson Inv Mgmt holds 0.03% or 16,200 shares in its portfolio. Nationwide Fund has 19,480 shares for 0% of their US portfolio. Bogle Inv Mgmt Ltd Partnership De has invested 0.03% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Columbia Wanger Asset Mgmt Lc last reported 1.78 million shares in the company. State Bank Of Mellon Corporation, a New York-based fund reported 185,974 shares. Alliancebernstein Lp accumulated 41,630 shares or 0% of the stock. Blackrock holds 0% or 2,447 shares in its portfolio. Cookson Peirce Commerce Incorporated accumulated 0.02% or 13,575 shares. California State Teachers Retirement, a California-based fund reported 60,987 shares. Weiss Multi has invested 0.02% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Morgan Stanley reported 1,200 shares or 0% of all its holdings. Iguana Health Mgmt Lc has invested 0.18% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Highlander Cap Management Ltd Limited Liability Company has invested 0.04% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Lazard Asset Management Ltd Llc has 0.01% invested in the company for 318,175 shares.
Insider Transactions: Since November 1, 2016, the stock had 2 insider purchases, and 0 insider sales for $921,102 net activity. LEVIN CAPITAL STRATEGIES – L.P. had bought 159,200 shares worth $706,571 on Thursday, November 3.
More news for Fluidigm Corporation (NASDAQ:FLDM) were recently published by: Nasdaq.com, which released: “Fluidigm Corporation Adopts Tax Benefit Preservation Plan to Protect Its Net …” on November 22, 2016. Streetinsider.com‘s article titled: “Form 8-A12B FLUIDIGM CORP” and published on November 22, 2016 is yet another important article.
FLDM Company Profile
Fluidigm Corporation, incorporated on March 29, 2007, creates, makes and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Firm sells instruments and consumables, including integrated fluidic circuits, assays and reagents, to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies. The Firm operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. The Firm offers various types of products, which include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.